Concepedia

Author

Takahiko Sugihara

Tokyo Medical and Dental UniversityORCID

Also Known As

Atsuo Nakajima, Atsushi Kumanogoh, Shogo Banno, Sugihara, Takahiko, T Sugihara, T. Sugihara, Takahiko SUGIHARA, Takahiko Sugihara

138

Publications

2.4K

Citations

27

H-Index

45

Concepts

All Affiliations

Tokyo Medical and Dental UniversityTokyo Women's Medical UniversityKyorin UniversityTokyo Metropolitan Geriatric HospitalKyoto University
TS

About

Takahiko Sugihara is an author at Tokyo Medical and Dental University specializing in medicine, rheumatology, and autoimmune disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

359

2

Epidemiology

3

3

103

3

Public Health

2

2

31

4

Allergy

2

2

61

5

Clinical Immunology

1

1

10

Takahiko Sugihara

×

41

Publications

1.6K

Citations

22

H-Index

YearCitations

The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease

Takahiko Sugihara, Ayako Kobori, Hirotsugu Imaeda,

Clinical & Experimental Immunology

2010

128

Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis

Kayoko Kaneko, Yoshishige Miyabe, Aiko Takayasu,

Arthritis Research & Therapy

2011

105

Successful Treatment of Animal Models of Rheumatoid Arthritis with Small-Molecule Cyclin-Dependent Kinase Inhibitors

Chiyoko Sekine, Takahiko Sugihara, Sachiko Miyake,

The Journal of Immunology

2008

102

Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication

Yutaka Kawahito, Akio Morinobu, Yuko Kaneko,

Modern Rheumatology

2022

100

Therapeutic effects of interleukin‐6 blockade in a murine model of polymyositis that does not require interleukin‐17A

Naoko Okiyama, Takahiko Sugihara, Yoichiro Iwakura,

Arthritis & Rheumatism

2009

95

Time‐dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis

Ryoko Sakai, Yukiko Komano, Michi Tanaka,

Arthritis Care & Research

2012

89

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Ryoko Sakai, Soo‐Kyung Cho, Toshihiro Nanki,

Arthritis Research & Therapy

2015

72

A new murine model to define the critical pathologic and therapeutic mediators of polymyositis

Takahiko Sugihara, Chiyoko Sekine, Takashi Nakae,

Arthritis & Rheumatism

2007

71

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules

Ryoko Sakai, Michi Tanaka, Toshihiro Nanki,

Annals of the Rheumatic Diseases

2012

57

Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE)

Takahiko Sugihara, Tatsuro Ishizaki, Tadashi Hosoya,

Lara D. Veeken

2014

56

Page 1